NUVB

3.7950.39%
KE

Kathryn E. Falberg

Independent Director

Ms. Kathryn E. Falberg, also known as Kate, serves as an Independent Director at Nuvation Bio, Inc. since October 2020. She has been Independent Director at Tricida, Inc. since May 2018. She serves as the Director of Ariosa Diagnostics, Inc. She had been Director at The Trade Desk, Inc. since August 2016 until 2026. She had been Director at Aimmune Therapeutics, Inc., since May 2015 until October 13, 2020. Ms. Falberg served as Director of Urogen Pharma Ltd. since April 2017 until June 08, 2022. She has been Independent Director at Arcus Biosciences, Inc. since September 18, 2017. She previously served as Executive Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc from March 2012 to March 2014 after serving as Senior Vice President and Chief Financial Officer since December 2009. From 2001 to 2009, she served as a Corporate Director for several companies. From 1995 to 2001, she was with Amgen Inc. where she served as Senior Vice President, Finance and Strategy and Chief Financial Officer and prior to that as Chief Accounting Officer, Controller and Vice President, Treasurer. Ms. Falberg also serves as a Director for the public biopharmaceutical companies. She served as Director of Axovant Sciences Ltd. since April 10, 2017 until February 12, 2018, aTyr Pharma, Inc. and BioMarin Pharmaceutical Inc. From 2001 to 2009, she worked with several smaller companies while serving as a corporate director for several companies. She has extensive background in financial and accounting matters for public companies and has leadership experience in the biotechnology industry. She also served as Director of Medivation, Inc. from 2013 to 2016 and Halozyme Therapeutics, Inc. from 2007 to 2016. Ms. Falberg received an M.B.A. in Finance and B.A. in Economics from the University of California Los Angeles and is a Certified Public Accountant (inactive).

Positions